Source: International Congress 2016 – ERS and tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Christian Lienhardt (Marseille, France). The new WHO TPPs (Target Product Profiles) for new TB treatment regimens. International Congress 2016 – ERS and tuberculosis

Member's Comments

No comment yet.

Related content which might interest you: Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016 Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Rational use of new TB drugs in the EU Source: Annual Congress 2012 - New guidelines in respiratory infections Year: 2012 ²Cost analysis of tuberculosis Directly Observed Treatment Strategy (DOTS) at chest dispensaries² Source: Eur Respir J 2005; 26: Suppl. 49, 143s Year: 2005 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Confirmation of preclinical data on tioureidoiminomethylpyridinium perchlorate in treatment of MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Tuberculosis diagnostics: which target product profiles should be prioritised? Source: Eur Respir J 2014; 44: 537-540 Year: 2014 Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016